| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b129d6d51f068ea4bf41406876772dc1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73a968b904f24af6cd348b6d3d1c9eb4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-455 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2008-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a840932140cb7a2529b38e2f8422ab5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c633d25a326b6ff2427890bc6334f470 |
| publicationDate |
2009-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009162454-A1 |
| titleOfInvention |
Compositions and Methods for Effecting NAD+ Levels Using A Nicotinamide Phosphoribosyl Tranferase Inhibitor |
| abstract |
The present invention relates to methods for decreasing cellular DNA repair in a target patient; decreasing cellular NAD + biosynthesis in a target patient; increasing efficiency of radiation therapy in a target patient; modulating nicotinamide phosphoribosyl transferase activity in a patient; or sensitizing a patient to a DNA damaging therapy. The invention relates to methods for treating a patient who received a toxic dose of an nicotinamide phosphoribosyl transferase inhibitor. The invention also relates to pharmaceutical compositions comprising a physiologically acceptable carrier; an effective amount of a NMPRT inhibitor; and nicotinic acid. The invention also relates to methods for treating a patient diagnosed with or suspected to have a cancer deficient in nicotinic acid pathway. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8912184-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103929961-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012177782-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9676721-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112843058-A |
| priorityDate |
2007-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |